TAYSHA GENE THERAPIES INC
NASDAQ: TSHA (Taysha Gene Therapies, Inc.)
Last update: 22 hours ago4.10
-0.11 (-2.61%)
| Previous Close | 4.21 |
| Volume | 2,474,566 |
| Price / Sales | 280.23 |
| Price / Book | 3.74 |
| 52 Weeks Range |
| Operating Margin (TTM) | -930.54% |
| Diluted EPS (TTM) | -0.340 |
| Quarterly Revenue Growth (YOY) | -32.50% |
| Total Debt/Equity (MRQ) | 111.93% |
| Current Ratio (MRQ) | 5.35 |
| Operating Cash Flow (TTM) | -83.45 M |
| Levered Free Cash Flow (TTM) | -52.28 M |
| Return on Assets (TTM) | -35.91% |
| Return on Equity (TTM) | -159.34% |
AIStockmoo Score
| Value 30% | -1.4 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| Return on Capital info | NA |
| Timing 30% | -2.4 |
| From our AI technical analysis of the chart. info | NA |
| No clear trend over the past year. Far below its 52-week high. info | |
| Candle Patterns info | NA |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| News Mood info | NA |
| Smart Money 20% | 3.2 |
| Insider Activity info | NA |
| Institutions net +10.38% of shares in their latest 13F filings: 137 holders increased, 74 decreased (quarter to 30 Sep 2026). info | |
| Short interest +14.3% from 31 Aug to 30 Oct 2026, 14.8 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Price is low against its 52-week average. Down over 5 years. info | |
| Short-term momentum rising. info | |
| Price is near support. Levels trending down. info | |
| Final Score | -0.49 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Taysha Gene Therapies, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| TSHA | - | - | - | 3.74 |
| VRNA | 9 B | - | - | 33.01 |
| OPT | 583 M | - | - | 4.31 |
| VRCA | - | - | - | 15.60 |
| ABEO | - | - | - | 1.04 |
| VKTX | - | - | - | 6.33 |
Select this tab to load the latest available analysis.
|
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 12.11% |
| % Held by Institutions | 67.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Polar Capital Holdings Plc | 30 Jun 2026 | 5,117,133 |
No data within this time range.
Institutions
Institutional ownership: 97.20%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 137 | 37,295,049 |
| Decreased | 74 | 15,115,926 |
| New | 43 | 16,801,077 |
| Sold out | 22 | 5,137,834 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 53,478,497 | 14.8 |
| 15 Oct 2026 | 51,249,292 | 11.6 |
| 30 Sep 2026 | 55,020,663 | 11.2 |
| 15 Sep 2026 | 51,405,384 | 18.8 |
| 31 Aug 2026 | 46,800,424 | 19.4 |
| 14 Aug 2026 | 46,738,149 | 17.4 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 13 Nov 2026 | Yahoo Finance |
Taysha (TSHA) Q3 2026 Earnings Call Transcript
Management says 33 patients dosed so far with no severe treatment-related events. |
| 12 Nov 2026 | Yahoo Finance |
Taysha Gene Therapies Q3 Earnings Call Highlights
Taysha Gene Therapies (NASDAQ:TSHA) expects to report pivotal trial data for its experimental Rett syndrome gene therapy TSHA-102 and provide feedback from U.S. regulators on a potential filing pathway in the first half of 2027, executives said on the company’s third-quarter earnings call. The comp… |
| 12 Nov 2026 | Yahoo Finance |
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027 TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across… |
| 06 Nov 2026 | Yahoo Finance |
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today… |
| 05 Nov 2026 | Yahoo Finance |
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today… |
| 30 Oct 2026 | Yahoo Finance |
Taysha Gene Therapies (TSHA) Stock Looks Rich Against Book Value
Taysha Gene Therapies has seen sharp swings in its share price over recent years, and that volatility puts a spotlight on a basic question for holders: Is the market value you see on screen today in line with what its balance sheet and book value can reasonably support? Over the past 3 years the… |
| 18 Oct 2026 | Yahoo Finance |
Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?
Taysha Gene Therapies reported phase 1/2 REVEAL data in Rett syndrome, where all 10 participants receiving a single intrathecal TSHA-102 dose gained or regained at least one developmental milestone and no treatment-related serious adverse events were observed. These findings support the therapy's… |
| 09 Oct 2026 | Yahoo Finance |
Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book Value
Taysha Gene Therapies has delivered a 90.1% gain over the past three years, which puts fresh attention on whether that kind of move is backed up by the value on its balance sheet. With the share price at US$4.43 at the last close, the live question is how comfortably that level sits against the… |
| 09 Oct 2026 | Yahoo Finance |
Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?
Taysha Gene Therapies (TSHA) has drawn fresh attention after a period of pressure on the share price, with the stock roughly flat over the past day but lower over the past month and the past three months. Short term momentum for Taysha Gene Therapies has clearly cooled, with the 7 day share price… |
| 01 Oct 2026 | Yahoo Finance |
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today… |
| 07 Sep 2026 | Yahoo Finance |
These 3 Risky Stocks Could Be Sitting on 100% Upside
Analysts see high-risk, high-reward potential in Red Cat Holdings, Taysha Gene Therapies, and Solaris Resources, each projected to roughly double despite significant company-specific risks. |
| 18 Aug 2026 | Yahoo Finance |
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
TSHA-102 dosing complete in pivotal Rett syndrome trials with 100% responder rate. |
| Show more | ||
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |